Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through lice... Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals. 詳細を表示
DURHAM, N.C., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.19 | -5.52325581395 | 3.44 | 3.8 | 3.25 | 1475220 | 3.57890286 | CS |
4 | 0.2956 | 10.0054156512 | 2.9544 | 3.8 | 2.705 | 1696537 | 3.20751187 | CS |
12 | 2.3789 | 273.091493514 | 0.8711 | 3.8 | 0.8101 | 4495871 | 2.62121088 | CS |
26 | 2.44 | 301.234567901 | 0.81 | 3.8 | 0.75 | 2218613 | 2.44503522 | CS |
52 | 2.23 | 218.62745098 | 1.02 | 3.8 | 0.75 | 1283367 | 2.26523409 | CS |
156 | -2.72 | -45.5611390285 | 5.97 | 6.52 | 0.75 | 1547373 | 2.25702627 | CS |
260 | 1.11 | 51.8691588785 | 2.14 | 11.5696 | 0.75 | 1243990 | 3.1876298 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約